IP Library Granted Patent US 11,207,348
Granted Patent B2
US 11,207,348 · App. 16/394,543 · Granted Dec 28, 2021

Spinel ferrite impregnated mesoporous silica containing a platinum complex

Inventors: B. Rabindran Jermy (Dammam, SA); Vijaya Ravinayagam (Dammam, SA); Abdulhadi Baykal (Dammam, SA)
Assignee: Imam Abdulrahman Bin Faisal University
A61K33/243A61K47/02A61P35/00A61K47/14B82Y5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,207,348
App. No.
16/394,543
Granted
Dec 28, 2021
Kind
B2
Abstract

A nanotherapeutic having platinum complexes encapsulated by a nanoformulation containing at least one spinel ferrite of formula CuFe 2 O 4 , NiFe 2 O 4 , CoFe 2 O 4 , and MnFe 2 O 4 deposited on mesoporous silica. A method of preparing the nanotherapeutic that involves mixing a metal(II) salt and a Fe(III) salt with the mesoporous silica nanoparticles to form a powdery mixture, calcining the powdery mixture to form the nanoformulation, and mixing the nanoformulation with the platinum complex. A method for treating cancer with the nanotherapeutic.

Claims (14)

1. A nanotherapeutic, comprising:

a nanoformulation, comprising:

mesoporous silica nanoparticles in the form of monodispersed spherical silica having a particle size distribution of about 80 nm; and

spinel ferrite nanoclusters of formula (I)

MFe 2 O 4   (I)

wherein M is at least one transition metal element selected from the group consisting of Cu and Ni;

wherein:

the spinel ferrite nanoclusters are impregnated on the mesoporous silica nanoparticles; and

the spinel ferrite nanoclusters are present in an amount of 25-35 wt % relative to a total weight of the nanoformulation, and

cisplatin encapsulated within pores of the nanoformulation,

wherein the nanoformulation has a cisplatin release at a pH 5 at 37° C. for 72 h of 60-80 wt. % and wherein the pores of the nanoformulation have a pore diameter in a range of 10-25 nm, and the nanoformulation has a pore volume in a range of 0.05 0.3 cm 3 /g, a BET surface area in a range of 15-70 m 2 /g, and a saturation magnetization value in a range of 7-15 emu/g.

2. The nanotherapeutic of claim 1 , wherein the cisplatin is present at a concentration of 0.01-10 mmol/g relative to a total weight of the nanoformulation.

3. The nanotherapeutic of claim 1 , further comprising one or more pharmaceutically acceptable carriers and/or excipients selected from the group consisting of a buffer, an inorganic salt, a fatty acid, a vegetable oil, a synthetic fatty ester, a surfactant, and a polymer.

4. The nanotherapeutic of claim 1 , wherein the spinel ferrite nanoclusters are paramagnetic.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2019
From: JERMY, B. RABINDRAN; RAVINAYAGAM, VIJAYA; BAYKAL, ABDULHADI
To: IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY
Reel/Frame 048997/0573 →
Continuity (1)
Related Publication 20200338122A1 · Oct 29, 2020